In both AML and ALL, UPR activation leads to elimination of misfolded proteins and apoptosis resistance through various mechanisms, such as enhancement of the ER-associated degradation (ERAD) and IRE1α-dependent decay (RIDD) responses 30-33. This evidence concerns the gene ERN1 and acute myeloid leukemia.